Connor, Clark & Lunn Investment Management (CC&L)’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $551K | Sell |
21,335
-3,219
| -13% | -$83.2K | ﹤0.01% | 1223 |
|
|
2025
Q1 | $250K | Sell |
24,554
-24,171
| -50% | -$247K | ﹤0.01% | 1291 |
|
|
2024
Q4 | $680K | Buy |
48,725
+5,336
| +12% | +$74.4K | ﹤0.01% | 1061 |
|
|
2024
Q3 | $846K | Buy |
43,389
+2,306
| +6% | +$45K | ﹤0.01% | 934 |
|
|
2024
Q2 | $764K | Buy |
41,083
+2,813
| +7% | +$52.3K | ﹤0.01% | 921 |
|
|
2024
Q1 | $536K | Buy |
38,270
+5,155
| +16% | +$72.2K | ﹤0.01% | 1084 |
|
|
2023
Q4 | $281K | Buy |
33,115
+317
| +1% | +$2.69K | ﹤0.01% | 1190 |
|
|
2023
Q3 | $293K | Sell |
32,798
-9,513
| -22% | -$85K | ﹤0.01% | 1151 |
|
|
2023
Q2 | $365K | Buy |
42,311
+12,429
| +42% | +$107K | ﹤0.01% | 1063 |
|
|
2023
Q1 | $315K | Buy |
29,882
+19,127
| +178% | +$202K | ﹤0.01% | 1001 |
|
|
2022
Q4 | $365K | Buy |
10,755
+10,041
| +1,406% | +$340K | ﹤0.01% | 946 |
|
|
2022
Q3 | $34K | Sell |
714
-1,808
| -72% | -$86.1K | ﹤0.01% | 1072 |
|
|
2022
Q2 | $144K | Sell |
2,522
-8,710
| -78% | -$497K | ﹤0.01% | 961 |
|
|
2022
Q1 | $908K | Buy |
11,232
+7,692
| +217% | +$622K | ﹤0.01% | 681 |
|
|
2021
Q4 | $717K | Buy |
+3,540
| New | +$717K | ﹤0.01% | 731 |
|
|
2021
Q3 | – | Sell |
-1,049
| Closed | -$270K | – | 1163 |
|
|
2021
Q2 | $270K | Buy |
+1,049
| New | +$270K | ﹤0.01% | 873 |
|
|
2020
Q1 | – | Sell |
-1,712
| Closed | -$554K | – | 1119 |
|
|
2019
Q4 | $554K | Buy |
+1,712
| New | +$554K | ﹤0.01% | 651 |
|
|
2014
Q2 | – | Sell |
-853
| Closed | -$171K | – | 603 |
|
|
2014
Q1 | $171K | Sell |
853
-2,274
| -73% | -$456K | ﹤0.01% | 632 |
|
|
2013
Q4 | $566K | Buy |
3,127
+2,367
| +311% | +$428K | ﹤0.01% | 468 |
|
|
2013
Q3 | $122K | Buy |
+760
| New | +$122K | ﹤0.01% | 477 |
|